MYOS Appoints Andrew J. Einhorn as Chief Financial Officer

MYOS Appoints Andrew J. Einhorn as Chief Financial Officer 
CEDAR KNOLLS, NJ -- (Marketwire) -- 10/18/12 --  MYOS Corporation
(OTCBB: MYOS), a company focused on the discovery, development and
commercialization of therapeutic products that improve muscle health
and performance, announced today the appointment of Andrew J. Einhorn
as its Chief Financial Officer.  
Mr. Einhorn has extensive knowledge of the pharmaceutical industry's
financial operations, due to his previous experience in senior
management positions at other pharmaceutical companies. Einhorn most
recently served as Executive Vice President and Chief Financial
Officer at Oceana Therapeutics, Inc. up until its sale to Salix
Pharmaceuticals in 2011. Prior to that, Mr. Einhorn served as
Executive Vice President and CFO of Esprit Pharma, Inc., where he was
responsible for the company's finances and was actively involved in
its sale to Allergan Inc. Mr. Einhorn also served as Executive Vice
President and CFO at ESP Pharma, Inc., where he managed the company's
finances until its sale to Protein Design Labs Inc. for approximately
a half-billion dollars. 
"With such a successful track record as the financial manager of
other pharmaceutical companies, we are thrilled to have Andrew
Einhorn on board at MYOS," said Peter Levy, Chief Operating Officer
of MYOS. "Andrew's experience and financial acumen make him a perfect
choice to guide us through the expansion of our business, and we are
excited to work with him." Mr. Einhorn stated, "I was attracted to a
terrific product opportunity and the team at MYOS and I look forward
to helping guide the company's business strategy and positioning it
for future growth." 
Prior to his work in the pharmaceutical industry, Mr. Einhorn spent
nearly twenty years in the banking industry, where he served as
Managing Director with Credit Lyonais Securities, PNC Capital
Markets, Bankers Trust Company, Chase Securities and Chase Manhattan
Bank. Mr. Einhorn started his career with Touche Ross & Company,
where he served as a senior accountant responsible for managing
audits for healthcare and other industry clients, giving him a
different perspective of the finances of healthcare companies. 
Additional information regarding this appointment is available in 
a
Form 8-K filed by MYOS with the Securities and Exchange Commission on
October 15, 2012. 
About MYOS Corporation 
MYOS is a development stage company focused on the discovery,
development and commercialization of therapeutic products that
improve muscle health and performance. MYOS is the owner of MYO-T12,
the world's first clinically demonstrated myostatin inhibitor.
Myostatin is a natural regulatory protein, which inhibits muscle
growth and recovery. MYO-T12 is manufactured to optimize biological
activity, which MYOS believes has the potential to redefine existing
standards of physical health and wellness enhancement. For more
information on MYO-T12 and to discover why MYOS is known as "The
Muscle Company,"(TM) visit www.myoscorp.com. 
Forward-Looking Statements 
Any statements in this release that are not historical facts are
forward-looking statements. Actual results may differ materially from
those projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not limited
to those relating to product and customer demand, market acceptance
of our products, the ability to create new products, the ability to
achieve a sustainable profitable business, the effect of economic
conditions, the ability to protect our intellectual property rights,
competition from other providers and products, risks in product
development, our ability to raise capital to fund continuing
operations, and other factors discussed from time to time in the
Company's Securities and Exchange Commission filings. The Company
undertakes no obligation to update or revise any forward-looking
statement for events or circumstances after the date on which such
statement is made except as required by law. 
These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure
or prevent any disease. 
Contact: 
Investor Contact
CEOcast, Inc.
Bob Woods
212-732-4300
Investor Relations
rwoods@ceocast.com 
 
 
Press spacebar to pause and continue. Press esc to stop.